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Background
Severe food allergy is a life threatening condition with
few therapeutics alternatives. A pilot study with omali-
zumab, as an alternative treatment in persistent milk
and egg allergy, has been conducted.
Methods
Children above 6 years with IgE-mediated allergy to
milk or egg. Anaphylaxis history and positive skin prick
test (SPT) and sIgE levels against food. Informed con-
sent was required.
Patients received a sixteenth week treatment with anti
IgE Omazilumab. SPT and single blind food challenges
(SBFC) were performed after the treatment. Adverse
reactions were registered.
Results
Ten patients were included, 3 patients suffered allergy to
milk and 7 to egg . They had a positive SBFC or a pre-
vious history of food transgressions with reactions in the
last six months. All patients received anti-IgE treatment
without any significant adverse reaction. After 16 weeks,
eight patients underwent to SBFC and complete toler-
ance was confirmed in four patients. Four patients pre-
sented a positive SBFC. All subjects reached a higher
dose threshold than baseline SBFC. Two patients
rejected SBFC. 6 patients with anaphylactic allergy were
allocated in a specific oral tolerance induction (SOTI)
with anti IgE treatment. During SOTI, only one subject
experienced some mild side-effects, 2 patients success-
fully completed the treatment, and 4 patients still con-
tinue with their SOTI procedure without any significant
reactions during in-patient administered doses or out-
patient maintenance doses.
Conclusions
Anti-IgE therapy has proven an effective and safe mea-
sure in the treatment of the persistent and severe allergy
to milk and egg, whether used as monotherapy or as an
adjuvant measure to the process of desensitization to
food, making it safer and faster procedure.
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